Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Patient-Entered Wellness Data Increases Preventive Care

Published: Tue, 17 Oct 2017 12:00:00 EDT
A new tool collects patient-entered data and provides personalized preventive care recommendations in several wellness areas.
Journal of the American Board of Family Medicine

What Counts as Cheating During Medical School Exams?

Published: Tue, 17 Oct 2017 12:00:00 EDT
Intentional or not, sharing information about medical school exams may be considered cheating and could lead to serious repercussions.
Student BMJ

FOXP1-Related Intellectual Disability Syndrome

Published: Tue, 17 Oct 2017 12:00:00 EDT
FOXP1 defects have been implicated in the pathogenesis of intellectual disability and speech and language impairment.
Journal of Medical Genetics

Ketamine vs Ketamine and Propofol for Procedural Sedation

Published: Tue, 17 Oct 2017 12:00:00 EDT
Might the co-administration of ketamine and propofol for pediatric procedural sedation offer additional benefits over ketamine alone?
The Journal of Emergency Medicine
Displaying results 17-20 (of 20)
 1 - 2 - 3 - 4 - 5 


Trevena sheds scientific staff and CSO to focus on lead pain drug

Published: Thu, 12 Oct 2017 13:13:23 +0000
Around a third of Trevena’s workforce are facing the ax as the biotech throws all its weight behind soon-to-be-filed injectable pain therapy Olinvo.

Averting toxic side effects from CAR-T cancer treatments

Published: Thu, 12 Oct 2017 12:35:42 +0000
Scientists at Fred Hutchinson Cancer Research Center said they’ve identified biomarkers associated with cytokine release syndrome and neurotoxicity, two side effects that can occur in cancer patients treated with CAR-T cells. And they’ve created algorithms to predict when the effects are likely to be life-threatening.

Merck writes off big bet on CETP drug anacetrapib

Published: Thu, 12 Oct 2017 12:18:46 +0000
Merck, the last big firm standing in the once-hyped CETP field, has opted against filing for approval of anacetrapib. The Big Pharma reached the decision after going over a mixed set of data from its big bet on a phase 3 program.

Ardelyx rises on better IBS data and a clearer path to FDA filing

Published: Thu, 12 Oct 2017 12:11:33 +0000
Small-cap biotech Ardelyx now has a second and more positive phase 3 trial for its constipation-predominant irritable bowel syndrome drug tenapanor, setting up regulatory filings next year.
Displaying results 17-20 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy